<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-136966</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Dermatomyositis and myastenia gravis: an uncommon association with therapeutic implications</dc:title>
<dc:description xml:lang="en">The association of dermatomyositis with myasthenia gravis (MG) is uncommon, having been reported so far in only 26 cases. We report the case of a 69 year-old man diagnosed with MG two years ago and currently treated with piridostigmyne. The patient developed acute proximal weakness, shoulder pain and elevated creatine-kinase (CK). He also developed generalized facial erythema and Gottron's papules. Laboratory tests showed positive antinuclear and anti-Mi2 antibodies. Further analysis confirmed CK levels above 1000 U/l. The clinical management of the patient and the therapeutic implications derived from the coexistence of both entities are discusssed (AU)</dc:description>
<dc:creator>Andréu, José Luis</dc:creator>
<dc:creator>Sangüesa Gómez, Clara</dc:creator>
<dc:creator>Godoy, Hildegarda</dc:creator>
<dc:creator>Méndez Perles, Clara</dc:creator>
<dc:creator>Flores Robles, Bryan Josué</dc:creator>
<dc:creator>Barbadillo, Carmen</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La asociación de dermatomiositis y miastenia gravis (MG) es infrecuente, habiéndose comunicado hasta la actualidad únicamente 26 casos. Se presenta el caso de un varón de 69 años diagnosticado de MG 2 años atrás, en tratamiento con piridostigmina, que inicia cuadro agudo de debilidad muscular proximal, artralgias en hombros y elevación de creatincinasa (CK); así como aparición de eritema facial generalizado y pápulas de Gottron. En el estudio de laboratorio se evidenció positividad de anticuerpos antinucleares y anti-Mi2. Ulteriores determinaciones de CK mostraron niveles por encima de 1.000 U/l. Se discute el manejo clínico de este paciente y las implicaciones terapéuticas que plantea la coexistencia de ambas entidades (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);11(4): 244-246, jul.-ago. 2015. ilus</dc:source>
<dc:identifier>ibc-136966</dc:identifier>
<dc:title xml:lang="es">Dermatomiositis y miastenia gravis: una asociación infrecuente con implicaciones terapéuticas</dc:title>
<dc:subject>^d9349^s22012</dc:subject>
<dc:subject>^d32676^s29166</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9349^s29166</dc:subject>
<dc:subject>^d32676^s22016</dc:subject>
<dc:subject>^d28231</dc:subject>
<dc:subject>^d34524^s22074</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d9327^s22016</dc:subject>
<dc:subject>^d32676^s22012</dc:subject>
<dc:subject>^d32676^s22067</dc:subject>
<dc:subject>^d4977^s22012</dc:subject>
<dc:subject>^d22622^s22073</dc:subject>
<dc:subject>^d3902^s22012</dc:subject>
<dc:subject>^d32676^s22032</dc:subject>
<dc:subject>^d52421^s22021</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d3902^s29166</dc:subject>
<dc:subject>^d9327^s22012</dc:subject>
<dc:subject>^d53583</dc:subject>
<dc:type>article</dc:type>
<dc:date>201508</dc:date>
</metadata>
</record>
</ibecs-document>
